Find a study
Browse recruiting studies near you — free to check, always your choice.
79 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- DepressionAnxiety
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Testing whether therapy sessions can help teens and young adults with sickle cell cope with
📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →
The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.
- Asthma
The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges
Testing whether inhaling ATP to trigger cough is safe and repeatable in people with asthma
📍 Respiratory Research Lab · Hamilton, Ontario · Get directions →
The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known.
- Depression
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Testing whether a brain receptor change affects ketamine’s effect on depression
📍 Yale University · New Haven, CT · Get directions →
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
- Dementia / Alzheimer'sParkinson's disease
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson
📍 Domino's Farms · Ann Arbor, MI · Get directions →
The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.
- Dementia / Alzheimer's
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Testing the safety and how a drug works in people with Alzheimer’s
📍 Clinical Trial Site · Montreal, · Get directions →
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
- Depression
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Testing how dimethyltryptamine affects safety and depression symptoms
📍 Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, CT · Get directions →
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects.
- Depression
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
Testing whether a low-dose ketamine IV treatment is safe and workable in the ER for people with
📍 University of Kansas Strawberry Hill Campus · Kansas City, KS · +1 more US site · Get directions →
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
- Depression
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Testing how one-time exercise and ibuprofen affect bipolar depression symptoms
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order.
- DepressionAnxiety
ACT for Individuals With MNCD and Their Care Partners
Testing acceptance commitment therapy for depression and anxiety in dementia
📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →
This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.
- Depression
RCT of Psilocybin-assisted CBT for Depression
Testing psilocybin with cognitive-behavioral therapy for depression
📍 UCLA Semel Institute · Los Angeles, CA · Get directions →
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT.
- Dementia / Alzheimer's
Rifaximin SSD in Dementia Trial
Testing a new form of rifaximin to change gut microbes in people with dementia
📍 Richmond VA Medical Center · Richmond, VA · Get directions →
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
- Asthma
A Study of CDX-622 in Participants With Mild to Moderate Asthma
Testing the safety and how a medicine affects the body in adults with mild to moderate asthma
📍 University of California, San Francisco · San Francisco, CA · +3 more US sites · Get directions →
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
- Depression
Psilocybin for Treatment-Resistant Depression in Autism
Testing psilocybin plus talk therapy for depression in autistic adults
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020).
- Dementia / Alzheimer's
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Testing a gene therapy in people with a genetic form of frontotemporal dementia
📍 The Ohio State University (OSU) Wexner Medical Center · Columbus, OH · +2 more US sites · Get directions →
The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement.
- Dementia / Alzheimer's
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Using brain scans to study how HIV affects the brain during treatment
📍 Yale School of Medicne, Neuro ID Research Program · New Haven, CT · Get directions →
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy.
- Dementia / Alzheimer's
Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer
Testing an online program to help dementia caregivers share what they learn
📍 Texas Christian University · Fort Worth, TX · +1 more US site · Get directions →
The overarching goal of this work is to determine methods that improve caregiver education about the behavioral and psychological symptoms (BPSD) of dementia. The specific goal of this project is to extend our prior work to evaluate the impact of our educational intervention on caregivers' ability to transfer knowledge about the management of ADRD to real-world applied examples.
- Asthma
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Testing how different doses of a new medicine affect safety and the body in people with mild to
📍 Pfizer Clinical Research Unit - New Haven · New Haven, CT · Get directions →
The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people.
- Depression
DBS for Depression
Testing whether deep brain stimulation is safe and feasible for severe depression that hasn’t
📍 Zucker Hillside Hospital · Queens, NY · Get directions →
The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: * Is deep brain stimulation effective in treating treatment resistant depression?
- Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
Testing whether donor stem cells are safe and helpful for hard-to-treat bipolar depression
📍 The University of Texas Health Science Center at Houston · Houston, TX · Get directions →
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
- Dementia / Alzheimer's
Ferritin and Iron Burden in SAH sIRB
Testing how iron and ferritin levels relate to brain injury after ruptured aneurysms with dementia
📍 Univesity of Iowa Hospital and Clinics · Iowa City, IA · +1 more US site · Get directions →
Ruptured cerebral aneurysms lead to subarachnoid hemorrhage (SAH),that has a high morbidity and mortality rate, the severity of which is predicted by the "Hunt-Hess grade" (HHG). SAH leads to iron (Fe) and hemoglobin (Hb) accumulation in the brain, which is toxic for neurons.
- Dementia / Alzheimer's
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
Testing a medicine in people with dementia to lower brain tau protein
📍 Washington University in St. Louis · St Louis, MO · Get directions →
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells.
- Dementia / Alzheimer's
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
Testing a treatment called SNK01 in people with moderate Alzheimer’s disease
📍 Behavioral Research Specialists, LLC · Glendale, CA · +6 more US sites · Get directions →
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1.
- Depression
Pharmacologic Augmentation of TMS for Depression With D-serine
Testing whether adding D-serine to TMS sessions helps depression
📍 McLean Hospital · Belmont, MA · Get directions →
The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.
- Depression
Neural Response to Inflammatory Challenge in Major Depressive Disorder
Testing brain and immune responses to an inflammation trigger in depression
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus.
- DepressionAnxiety
Open-Label Psilocybin Study in Transdiagnostic Population
Testing psilocybin for safety and symptom changes in people with depression or anxiety
📍 Connecticut Mental Health Center - Yale School of Medicine · New Haven, CT · Get directions →
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.
- Dementia / Alzheimer'sMultiple sclerosis (MS)
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Testing how an imaging tracer works in people with memory loss and multiple sclerosis
📍 Yale University PET Center · New Haven, CT · Get directions →
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
- DepressionAnxiety
Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
Testing a chatbot to support people using cannabis with anxiety or depression
📍 46 Centerra Parkway, Suite 300, Office #333S · Lebanon, NH · Get directions →
This study tests a chatbot called Therabot-CALM to help people who use cannabis with anxiety and/or low mood. Participants will do questionnaires, try the chatbot for 4 weeks, and join virtual interviews to give feedback on how usable and helpful it feels. The goal is to see if the chatbot is acceptable to users and can improve symptoms.
- Dementia / Alzheimer's
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Testing how a new medicine works in healthy adults and early Alzheimer’s disease
📍 Research Site 3 · East York, Ontario · Get directions →
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
- Depression
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
Testing how psilocybin affects the brain in people with hard-to-treat bipolar depression
📍 Toronto Western Hospital - University Health Network · Toronto, Ontario · Get directions →
This study is an open-label, single-arm, proof-of-concept study, wherein treatment resistant bipolar depression (TRBD) participants will receive one 25 mg dose of oral psilocybin accompanied by preparatory, monitoring, and integration psychotherapy sessions (psilocybin-assisted psychotherapy, or PAP). Using fMRI (functional magnetic resonance imaging), the findings of this study will provide data on the neurobiological mechanism of psilocybin in TRBD.
- Dementia / Alzheimer's
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
Testing time-limited eating to see if it improves sleep and brain changes in early Alzheimer’s or
📍 Shiley Marcos Alzheimer's Disease Center · San Diego, CA · Get directions →
The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults.
- Dementia / Alzheimer's
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Testing the safety and effects of ACI-24.060 in Alzheimer’s and Down syndrome
📍 Barrow Neurological Institute · Phoenix, AZ · +12 more US sites · Get directions →
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
- Depression
Theta-Burst Stimulation to Treat Depression
Testing a non-invasive brain stimulation approach to treat depression
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
The goal of this clinical trial is to explore the effects of non-invasive brain stimulation protocols using intermittent theta-burst stimulation (iTBS) on brain plasticity and depression severity in depressed individuals aged 18 to 50 years old. Brain plasticity is the brain's ability to change through growth or reorganization.
- Dementia / Alzheimer's
Nicotinic Acid for the Treatment of Alzheimer's Disease
Testing how well extended-release niacin reaches spinal fluid in dementia
📍 IU Health Neuroscience Center · Indianapolis, IN · Get directions →
Increased dietary intake of niacin is correlated with reduced risk of Alzheimer's Disease and age-associated cognitive decline. The goal of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid.
- Dementia / Alzheimer's
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Testing whether a new drug is safe in people with early Alzheimer’s
📍 K2 Medical Research, LLC · Maitland, FL · +5 more US sites · Get directions →
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.
- Depression
Personalized Ultrasonic Brain Stimulation for Depression (R61)
Testing a personalized, noninvasive brain stimulation for depression
📍 University of Utah · Salt Lake City, UT · Get directions →
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring.
- Depression
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
Testing ketamine with group therapy for Spanish-speaking adults with depression
📍 Massachusetts General Hospital, Chelsea · Chelsea, MA · Get directions →
This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression
- Dementia / Alzheimer's
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
Testing deep rTMS on a brain area for people with probable Alzheimer dementia to see if it is safe
📍 UCLA TMS Clinical and Research Service · Los Angeles, CA · Get directions →
The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects.
- Dementia / Alzheimer's
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
Testing the safety and effects of ABBV-1758 in people with Alzheimer’s disease given as injections
📍 Irvine Center for Clinical Research /ID# 277752 · Irvine, CA · +10 more US sites · Get directions →
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness.
- Depression
Psilocybin in Chronic Low Back Pain and Depression
Testing psilocybin’s effects on chronic low back pain and depression
📍 Johns Hopkins University School of Medicine · Baltimore, MD · Get directions →
This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose).
- Dementia / Alzheimer's
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
Testing a rideshare with a trained driver to help people with dementia get to medical visits
📍 Onward Health HQ · San Leandro, CA · Get directions →
The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD. Participants will be assigned either door-through-door (D2D) rideshare or curb-to-curb (C2C) rideshare services.
- Dementia / Alzheimer's
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
Testing a vaccine for early Alzheimer’s disease biomarkers for safety
📍 Comprehensive Center for Brain Health · Boca Raton, FL · +2 more US sites · Get directions →
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65-80 with biomarker evidence of early Alzheimer's disease will be enrolled into three ascending dose cohorts.
- Dementia / Alzheimer's
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
Testing the safety and how a medicine affects the body in early Alzheimer’s
📍 Montreal Neurological Institute Clinical Research Unit · Montreal, Quebec · Get directions →
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
- Depression
Pattern Separation in Major Depressive Disorder
Testing how depression treatments affect thinking, brain activity, and symptoms
📍 New York State Psychiatric Institute (NYSPI) · New York, NY · Get directions →
This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.
- Dementia / Alzheimer's
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Testing brain scans that measure PDE4 in people with dementia
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Depression
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Testing whether EEG gamma activity can predict 4-week ketamine treatment results for depression
📍 Wells Medicine · Houston, TX · +1 more US site · Get directions →
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion.
- Dementia / Alzheimer's
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Testing a treatment with IL-2 and semaglutide in people with Alzheimer's
📍 Houston Methodist Research Institute · Houston, TX · Get directions →
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Asthma
Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma
Testing safety and how a single inhaled dose works in adults with asthma
📍 Sun City Clinical Research · Glendale, AZ · +1 more US site · Get directions →
This is a phase 1 study, randomized, double-blind, placebo-controlled, 2 treatment, 2 period crossover study to evaluate the pharmacokinetics, safety, and tolerability of a single inhaled dose of ASY202 in adults with stable asthma. Following screening, eligible participants will be enrolled and randomized to one of two treatment sequences.
- Dementia / Alzheimer's
Low-Dose Radiotherapy for Alzheimer's Disease
Testing low-dose whole-brain radiation safety in people with Alzheimer’s or dementia
📍 Renaissance Institute of Precision Oncology & Radiosurgery · Winter Park, FL · Get directions →
To evaluate the safety and tolerability of low-dose whole brain radiotherapy (WBRT) delivered as an induction course of 0.3 Gy × 10 fractions (3.0 Gy total) followed by 12 months of monthly maintenance LDRT (0.3 Gy × 10 fractions; 3.0 Gy total) in patients with Alzheimer's disease or dementia with inflammatory components
- Depression
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Testing how ketamine affects brain imaging and blood markers in depression
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments.
- Dementia / Alzheimer's
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
Studying brain tau in people with dementia using a PET scan
📍 UAB · Birmingham, AL · Get directions →
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study.
- Depression
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Studying how ketamine may help depression work faster in people with treatment-resistant depression
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours.
- Dementia / Alzheimer'sParkinson's disease
[18F]F-DOPA Imaging in Patients With Autonomic Failure
Testing [18F]F-DOPA brain scans in people with autonomic failure
📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →
Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and/or glia. The anatomical location of alpha-synuclein inclusions (Lewy Bodies) and the pattern of progressive neuronal death (e.g.
- DepressionAnxiety
Affect of Duavive on Mood & Anxiety Symptoms
Testing how Duavive affects mood and anxiety symptoms in early menopause women
📍 St Joseph's Healthcare · Hamilton, Ontario · Get directions →
This study evaluates the impact of conjugated estrogens/ bazedoxifene (CE/ BZA) on the mood (depression and anxiety) in peri- and early menopausal women.
- Dementia / Alzheimer's
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Testing the safety and side effects of a medicine in early Alzheimer’s
📍 Collaborative Neuroscience Network - CNS · Los Alamitos, CA · +10 more US sites · Get directions →
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD).
- Dementia / Alzheimer's
A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.
Testing an implanted brain stimulation procedure to treat dementia from Alzheimer’s
📍 Wellstar MCG Hospital, Neurology Memory Clinic · Augusta, GA · Get directions →
The purpose of this study is to test a new procedure to treat Alzheimer's disease. The procedure is called intermittent Deep Brain Stimulation (DBS) of the nucleus basalis of Meynert.
- Depression
Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels
Testing low-intensity TMS for depression and for blood brain markers
📍 High Specialty Medical Unit No. 1, Bajío. Mexican Social Security Institute · León, Guanajuato · Get directions →
The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived neurotrophic factor (BDNF). TMS works to treat MDD by using low-intensity magnetic fields to modulate certain areas of the brain, activating them which can help improve the mood of those suffering from the disorder.
- Dementia / Alzheimer's
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Testing the safety and side effects of a medicine given into the spinal fluid for early-onset
📍 Clinical Trial Site · La Jolla, CA · +1 more US site · Get directions →
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose.
- Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD
📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
- Depression
qEEG Brain Signature of Depression & Neuromodulation-induced Recovery
Testing how rTMS treatment for depression changes brain activity
📍 Sunnybrook Health Sciences Centre · North York, Ontario · Get directions →
This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior.
- Depression
Psilocybin to Treat Depression in Spinal Cord Injury
Testing whether psilocybin is safe for depression in people with spinal cord injury
📍 James J. Peters Department of Veterans Affairs Medical Center · The Bronx, NY · Get directions →
The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg).
- Showing the first 60 of 79. Add filters or a location to narrow down.